摘要
目的:探讨p53、p16改变对进展期非小细胞肺癌(NSCLC)化疗疗效的影响。方法:检测一组进展期NSCLCp53、p16蛋白表达,分析其与常规化疗的关系。结果:NSCLC病例126例,Ⅲ期58例,Ⅳ期68例;p53阳性64例(51.0%),p16阴性74例(59.0%)。p53阳性患者化疗有效率为25.0%,p53阴性化疗有效率为57.0%,两者相差显著(p=0.004)。结论:探讨了联合化疗治疗进展期NSCLC与p53表达的关系,对晚期肺癌的综合治疗有一定指导意义。
Objective： To study the relationship between p53, p16 immunostainig, apoptosis related genes, and response to conventional chemotherapy in advanced non - small - cell lung eancer（NSCLC） in order to improve the prognosis of NSCLC. Methods： 126 cases（male 110 and female 16） were selected, mean age 63 years. Of these cases, 58 cases were stage Ⅲ and 68 were stage Ⅳ. The histological specimens obtained by bronchofibroscope and pricking biopsy from the lungs and metastasis lymph nodes of these subjects who underwent conventional chemotherapy were tested by p53, p16 immunostaining and evaluated. Results： 64 tumor specimens（51%） were positive to p53 immunostaining and 74 （59%） ones were negative to p16 immunostaining. The response rate of the group with p53 positive immunostaining was 26% versus 57% of the p53 negative group（p=0. 004）. Conclusion： It is confirmed that p53 expression is related to response rate in advanced NSCLC patients treated with convenient chemotherapy.
出处
《西南国防医药》
CAS
2005年第2期141-143,共3页
Medical Journal of National Defending Forces in Southwest China
关键词
非小细胞肺癌
P53
P16
化疗耐药
non-small- cell lung cancer, chemotherapy, p53, p16, resistance
